Xeltis AG - Product Pipeline Analysis, 2017 Update

Summary

Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. Its polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process referred to as endogenous tissue restoration (ETR). Based on supramolecular chemistry, the company develops bioabsorbable synthetic heart valves and vascular grafts to replace defective heart valves and blood vessels. ETR enables the patients natural healing system to develop tissue that spreads into the heart valve of Xeltis, building a new and natural valve inside with full functionality. The implants of Xeltis get absorbed by the body in the course of time. The company also operates research and development centers, manufacturing facility in Eindhoven, the Netherlands. Xeltis is headquartered in Zurich, Switzerland.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Xeltis AG
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Xeltis AG Company Overview 4
Xeltis AG Company Snapshot 4
Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview 4
Xeltis AG Pipeline Analysis Overview 7
Xeltis AG - Key Facts 7
Xeltis AG - Major Products and Services 8
Xeltis AG Pipeline Products by Development Stage 9
Xeltis AG Ongoing Clinical Trials by Trial Status 11
Xeltis AG Pipeline Products Overview 13
Endogenous Tissue Growth Implant 13
Endogenous Tissue Growth Implant Product Overview 13
Transcatheter Aortic Heart Valve 14
Transcatheter Aortic Heart Valve Product Overview 14
Xeltis Pulmonary Valve 15
Xeltis Pulmonary Valve Product Overview 15
Xeltis Pulmonary Valve Clinical Trial 16
Xeltis AG - Key Competitors 17
Xeltis AG - Key Employees 18
Xeltis AG - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Xeltis AG, Recent Developments 20
May 17, 2017: Xeltis Technology for Natural Heart Valve Restoration Featured as the Future of Valve Therapy at EuroPCR 20
Nov 01, 2016: Xeltis Announces Multidisciplinary Scientific Advisory Board of Global Leading Experts 20
Oct 05, 2016: Patients Implanted with Xeltis Bioabsorbable Cardiovascular Device Showed Positive Functionality Results Two Years After Surgery - Data at EACTS 21
Oct 03, 2016: First Heart Valve That Enables Cardiovascular Restoration Successfully Implanted in Three Patients in Xplore-I Clinical Trial 22
May 17, 2016: First Clinical Use of Bioabsorbable Vascular Grafts in Children Shows Promise 22
Mar 23, 2016: US FDA granted Humanitarian Use Device for Xeltis pulmonary valve 23
Nov 10, 2015: Xeltis completed second feasibility clinical trial on bioabsorbable cardiovascular device technology 23
Nov 05, 2015: Eliane Schutte joins the Xeltis Executive Team as Chief Development Officer 24
May 19, 2015: Xeltis Completes First-Ever Study of Endogenous Tissue Growth Technology 24
May 18, 2015: Innovative Cardiovascular Company Xeltis Nominates Michel Darnaud for Election to Its Board of Directors 24
Appendix 26
Methodology 26
About GlobalData 28
Contact Us 28
Disclaimer 29

List Of Tables

List of Tables
Xeltis AG Pipeline Products and Ongoing Clinical Trials Overview 4
Xeltis AG Pipeline Products by Equipment Type 5
Xeltis AG Pipeline Products by Indication 6
Xeltis AG Ongoing Clinical Trials by Trial Status 6
Xeltis AG, Key Facts 7
Xeltis AG, Major Products and Services 8
Xeltis AG Number of Pipeline Products by Development Stage 9
Xeltis AG Pipeline Products Summary by Development Stage 10
Xeltis AG Ongoing Clinical Trials by Trial Status 11
Xeltis AG Ongoing Clinical Trials Summary 12
Endogenous Tissue Growth Implant - Product Status 13
Endogenous Tissue Growth Implant - Product Description 13
Transcatheter Aortic Heart Valve - Product Status 14
Transcatheter Aortic Heart Valve - Product Description 14
Xeltis Pulmonary Valve - Product Status 15
Xeltis Pulmonary Valve - Product Description 15
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Feasibility of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction 16
Xeltis Pulmonary Valve - Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction 16
Xeltis AG, Key Employees 18
Xeltis AG, Subsidiaries 19
Glossary 27

List Of Figures

List of Figures
Xeltis AG Pipeline Products by Equipment Type 5
Xeltis AG Pipeline Products by Development Stage 9
Xeltis AG Ongoing Clinical Trials by Trial Status 11

Xeltis AG - Product Pipeline Analysis, 2019 Update

Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. Its polymer-based technology platform, RestoreX, facilitates the

USD 750 View Report

Xeltis AG - Medical Equipment - Deals and Alliances Profile.

Xeltis AG (Xeltis) is a medical device company that develops implantable products to function as natural heart valves and vessels. The comapny develops bioabsorbable synthetic heart valves and vascular grafts

USD 250 View Report

Benteler International AG - Strategy, SWOT and Corporate Finance Report

Benteler International AG - Strategy, SWOT and Corporate Finance ReportBenteler International AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report

USD 175 View Report

RUAG International Holding AG - Strategy, SWOT and Corporate Finance Report

RUAG International Holding AG - Strategy, SWOT and Corporate Finance ReportRUAG International Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information.

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available